All Relations between Epilepsy and Tuberous Sclerosis

Publication Sentence Publish Date Extraction Date Species
Michael LoPresti, Ataru Igarashi, Yaoki Sonohara, Sally Bowditc. A quantitative cross-sectional study of the burden of caring for patients with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex-associated epilepsy in Japan. Epilepsy & behavior : E&B. vol 154. 2024-03-31. PMID:38555725. lennox-gastaut syndrome (lgs), dravet syndrome (ds), and tuberous sclerosis complex (tsc)-associated epilepsy are rare conditions associated with severe childhood-onset epilepsy. 2024-03-31 2024-04-03 Not clear
Jingyi Tong, Tingting Ji, Ting Liu, Jiaqi Liu, Yibin Chen, Zongjun Li, Na Lu, Qifu L. Efficacy and safety of six new antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: A systematic review and network meta-analysis. Epilepsy & behavior : E&B. vol 152. 2024-01-26. PMID:38277848. this study aimed to evaluate the efficacy and safety of six new antiseizure medications (asms) for adjunctive treatment in adult patients with focal epilepsy and adolescents with dravet syndrome (ds), lennox-gastaut syndrome (lgs), or tuberous sclerosis complex (tsc). 2024-01-26 2024-01-29 Not clear
Zhirong Wei, Aria Fallah, Yangshuo Wang, Suhui Kuang, Alexader G Weil, Jiaqi Wang, Shuli Lian. Influence of resective extent of epileptogenic tuber on seizure outcome in patients with tuberous sclerosis complex-related epilepsy: A systematic review and meta-analysis. Seizure. vol 108. 2023-04-28. PMID:37116294. influence of resective extent of epileptogenic tuber on seizure outcome in patients with tuberous sclerosis complex-related epilepsy: a systematic review and meta-analysis. 2023-04-28 2023-08-14 Not clear
Dominika Śmiałek, Katarzyna Kotulska, Aleksandra Duda, Sergiusz Jóźwia. Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age. Neurology and therapy. 2023-04-21. PMID:37085686. effect of mtor inhibitors in epilepsy treatment in children with tuberous sclerosis complex under 2 years of age. 2023-04-21 2023-08-14 Not clear
Antônio Silvinato, Idevaldo Floriano, Wanderley Marques Bernard. Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Revista da Associacao Medica Brasileira (1992). vol 68. issue 10. 2022-11-23. PMID:36417631. use of cannabidiol in the treatment of epilepsy: lennox-gastaut syndrome, dravet syndrome, and tuberous sclerosis complex. 2022-11-23 2023-08-14 Not clear
Ashna Talwar, Emily Estes, Rajender Aparasu, Doodipala Samba Redd. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Experimental neurology. 2022-10-07. PMID:36206805. in this study, we evaluated the overall clinical potential of oral cbd to treat refractory epilepsy in patients with dravet syndrome (ds), lennox-gastaut syndrome (lgs), and tuberous sclerosis complex (tsc) through a systematic review and meta-analysis. 2022-10-07 2023-08-14 Not clear
Małgorzata Foryś-Basiejko, Katarzyna Kotulska, Agnieszka Maryniak, Agata Siłuszyk, Monika Szkop, Julita Borkowska, Monika Sugalska, Jagoda Głowacka-Walas, Sergiusz Jóźwia. Epilepsy and Language Development in 8-36-Month-Old Toddlers with Tuberous Sclerosis Complex. Journal of clinical medicine. vol 11. issue 15. 2022-08-12. PMID:35956179. epilepsy and language development in 8-36-month-old toddlers with tuberous sclerosis complex. 2022-08-12 2023-08-14 Not clear
Fuyi Zhang, Lingling Xie, Xiaoya He, Xiaojie Song, Helin Zheng, Longlun Wang, Li Jian. Tuber Brain Proportion Determines Epilepsy Onset in Children With Tuberous Sclerosis Complex. Pediatric neurology. vol 129. 2022-02-26. PMID:35217276. tuber brain proportion determines epilepsy onset in children with tuberous sclerosis complex. 2022-02-26 2023-08-13 Not clear
Lena H Nguyen, Steven C Leiser, Dekun Song, Daniela Brunner, Steven L Roberds, Michael Wong, Angelique Borde. Inhibition of MEK-ERK signaling reduces seizures in two mouse models of tuberous sclerosis complex. Epilepsy research. vol 181. 2022-02-26. PMID:35219048. tuberous sclerosis complex (tsc) is a monogenic disorder characterized by hyperactivation of the mtor signaling pathway and developmental brain malformations leading to intractable epilepsy. 2022-02-26 2023-08-13 mouse
Joyce Y Wu, Hannah R Cock, Orrin Devinsky, Charuta Joshi, Ian Miller, Colin M Roberts, Rocio Sanchez-Carpintero, Daniel Checketts, Farhad Sahebka. Time to Onset of Cannabidiol (CBD) Treatment Effect and Resolution of Adverse Events in Tuberous Sclerosis Complex: Post Hoc Analysis of Randomized Controlled Phase 3 Trial GWPCARE6. Epilepsia. 2022-02-17. PMID:35175622. to estimate the timing of cannabidiol (cbd) treatment effect (seizure reduction and adverse events [aes]) onset, we conducted a post hoc analysis of gwpcare6 (nct02544763), a randomized, placebo-controlled, phase 3 trial in patients with drug-resistant epilepsy associated with tuberous sclerosis complex (tsc). 2022-02-17 2023-08-13 Not clear
Linda Mc Koene, Eva Niggl, Ilse Wallaard, Martina Proietti-Onori, Diana C Rotaru, Ype Elgersm. Identifying the temporal electrophysiological and molecular changes that contribute to TSC-associated epileptogenesis. JCI insight. vol 6. issue 23. 2021-12-08. PMID:34877936. tuberous sclerosis complex (tsc), caused by heterozygous mutations in tsc1 or tsc2, frequently results in intractable epilepsy. 2021-12-08 2023-08-13 mouse
George H Korkar, Jean Isnard, Alexandra Montavont, Hélène Catenoix, Sylvain Rheims, Marc Guéno. Awake craniotomy for epilepsy surgery on eloquent speech areas: a single-centre experience. Epileptic disorders : international epilepsy journal with videotape. vol 23. issue 2. 2021-11-29. PMID:33926856. we conducted a retrospective cohort study of 17 consecutive patients with intractable partial seizures of different aetiologies (non-lesional epilepsy [n=3], tuberous sclerosis [n=1], hypoxic ischaemic insult [n=1], dysembryoplastic neuroepithelial tumours [dnet] [n=2], focal cortical dysplasia type 2 [fcd] [n=4], and other malformations of cortical development [n=6]), located in eloquent language cortex (frontal [n=7], insular [n=5], and latero-temporal [n=5] regions). 2021-11-29 2023-08-13 Not clear
Michael Won. mTOR as a potential treatment target for epilepsy. Future neurology. vol 7. issue 5. 2021-11-10. PMID:23620711. mtor inhibitors can suppress seizures and prevent epilepsy in animal models of certain genetic epilepsies, such as tuberous sclerosis complex. 2021-11-10 2023-08-12 Not clear
Mario Mastrangelo, Chiara Commone, Carlo Greco, Vincenzo Leuzz. TSC1 as a Novel Gene for Sleep-Related Hypermotor Epilepsy: A Child with a Mild Phenotype of Tuberous Sclerosis. Neuropediatrics. vol 52. issue 2. 2021-11-08. PMID:33578443. tsc1 as a novel gene for sleep-related hypermotor epilepsy: a child with a mild phenotype of tuberous sclerosis. 2021-11-08 2023-08-13 Not clear
Ling-Hui Zeng, Nicholas R Rensing, Michael Won. Developing Antiepileptogenic Drugs for Acquired Epilepsy: Targeting the Mammalian Target of Rapamycin (mTOR) Pathway. Molecular and cellular pharmacology. vol 1. issue 3. 2021-10-20. PMID:20419051. recent work implicates the mammalian target of rapamycin (mtor) pathway as mediating epileptogenesis in a genetic epilepsy, tuberous sclerosis complex (tsc), and suggests that mtor inhibitors, such as rapamycin, may have antiepileptogenic properties for epilepsy in tsc. 2021-10-20 2023-08-12 Not clear
Till S Zimmer, Anatoly Korotkov, Susan Zwakenberg, Floor E Jansen, Fried J T Zwartkruis, Nicholas R Rensing, Michael Wong, Angelika Mühlebner, Erwin A van Vliet, Eleonora Aronica, James D Mill. Upregulation of the pathogenic transcription factor SPI1/PU.1 in tuberous sclerosis complex and focal cortical dysplasia by oxidative stress. Brain pathology (Zurich, Switzerland). vol 31. issue 5. 2021-10-13. PMID:33786950. tuberous sclerosis complex (tsc) is a congenital disorder characterized by cortical malformations and concomitant epilepsy caused by loss-of-function mutations in the mtor suppressors tsc1 or tsc2. 2021-10-13 2023-08-13 Not clear
Marco de Curtis, Rita Garbelli, Laura Uv. A hypothesis for the role of axon demyelination in seizure generation. Epilepsia. vol 62. issue 3. 2021-09-21. PMID:33493363. loss of myelin and altered oligodendrocyte distribution in the cerebral cortex are commonly observed both in postsurgical tissue derived from different focal epilepsies (such as focal cortical dysplasias and tuberous sclerosis) and in animal models of focal epilepsy. 2021-09-21 2023-08-13 Not clear
Yehezkel Ben-Ari, Eric Delpir. Phenobarbital, midazolam, bumetanide, and neonatal seizures: The devil is in the details. Epilepsia. vol 62. issue 4. 2021-09-17. PMID:33534145. bum efficiently attenuates autism symptomatology notably in patients with tuberous sclerosis but does not reduce the recurrent seizures, illustrating the uniqueness of epilepsies. 2021-09-17 2023-08-13 Not clear
Wiebke Theilmann, Birthe Gericke, Alina Schidlitzki, Syed Muhammad Muneeb Anjum, Saskia Borsdorf, Timon Harries, Steven L Roberds, Dean J Aguiar, Daniela Brunner, Steven C Leiser, Dekun Song, Doriano Fabbro, Petra Hillmann, Matthias P Wymann, Wolfgang Lösche. Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex. Neuropharmacology. vol 180. 2021-08-27. PMID:32890589. the rapamycin derivative ("rapalog") everolimus, which allosterically inhibits the mtor pathway, is approved for the treatment of partial epilepsy with spontaneous recurrent seizures (srs) in individuals with tuberous sclerosis complex (tsc). 2021-08-27 2023-08-13 mouse
Longbo Zhang, Tianxiang Huang, Shannon Teaw, Lena H Nguyen, Lawrence S Hsieh, Xuan Gong, Lindsay H Burns, Angélique Borde. Filamin A inhibition reduces seizure activity in a mouse model of focal cortical malformations. Science translational medicine. vol 12. issue 531. 2021-06-23. PMID:32075941. epilepsy treatments for patients with mechanistic target of rapamycin (mtor) disorders, such as tuberous sclerosis complex (tsc) or focal cortical dysplasia type ii (fcdii), are urgently needed. 2021-06-23 2023-08-13 mouse